SCHEMBL3251304

SCHEMBL3251304

CCCc1ccc(S(=O)(=O)Nc2ncc(CC(=O)N3CCSCC3)s2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.49
▸ AKT1 P31749 5/20 0.42
▸ IRS1 P35568 3/20 0.42
▸ GAB1 Q13480 3/20 0.42
▸ TSHR P16473 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3248063 0.91 HPGD (0.51) HSD11B1AKT1IRS1GAB1TSHR
SCHEMBL3256147 0.90 TSHR (0.53) HSD11B1AKT1IRS1GAB1TSHR
SCHEMBL6624840 0.90 HSD11B1 (0.44) HSD11B1AKT1IRS1GAB1KMT2A
SCHEMBL3253320 0.89 HSD11B1 (0.50) HSD11B1AKT1IRS1GAB1TSHR
SCHEMBL3253323 0.89 HSD11B1 (0.50) HSD11B1AKT1IRS1GAB1TSHR
SCHEMBL3252292 0.84 HSD11B1 (0.51) HSD11B1MAPTKMT2AMEN1GAA
SCHEMBL5831265 0.83 AKT1 (0.59) AKT1IRS1GAB1TSHRALDH1A1
SCHEMBL3256711 0.82 AKT1 (0.56) AKT1IRS1GAB1ALDH1A1
SCHEMBL5831173 0.82 ALDH1A1 (0.43) AKT1IRS1GAB1TSHRALDH1A1
SCHEMBL3602414 0.81 HSD11B1 (0.49) HSD11B1AKT1IRS1GAB1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 — — EP claimed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 — — US claimed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 — — US claimed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US claimed
EP-1461325-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-05-26 — — EP disclosed
US-7671051-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2010-03-02 — — US disclosed
US-7094792-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-08-22 — — US disclosed
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 BIOVITRUM AB 2005-11-10 — — US disclosed
WO-2004112782-A1 NEW USE V BIOVITRUM AB (SE) 2004-12-29 — — WO disclosed
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250776-A1 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 HSD11B1, HSD17B1, HSD17B11 HSD11B1 1/4885AKT1 1528/4885IRS1 572/4885
US-20030130318-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885AKT1 1462/4885IRS1 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback